VRTX - Vertex Pharmaceuticals Inc Stock Price, Fair Value and News

394.04USD-6.72 (-1.68%)Delayed as of 25 Apr 2024, 11:53 am ET

Market Summary

USD394.04-6.72

Delayedas of 25 Apr 2024, 11:53 am

-1.68%

VRTX Alerts

1 major insider sales recently.

VRTX Stock Price

View Fullscreen

VRTX RSI Chart

VRTX Valuation

Market Cap

103.5B

Price/Earnings (Trailing)

28.6

Price/Sales (Trailing)

10.49

EV/EBITDA

20.62

Price/Free Cashflow

31.02

VRTX Price/Sales (Trailing)

VRTX Profitability

EBT Margin

44.38%

Return on Equity

20.59%

Return on Assets

15.92%

Free Cashflow Yield

3.22%

VRTX Fundamentals

VRTX Revenue

Revenue (TTM)

9.9B

Rev. Growth (Yr)

9.34%

Rev. Growth (Qtr)

1.38%

VRTX Earnings

Earnings (TTM)

3.6B

Earnings Growth (Yr)

18.31%

Earnings Growth (Qtr)

-6.42%

Breaking Down VRTX Revenue

52 Week Range

320.01403.83

(Low)(High)

Last 7 days

2.0%

Last 30 days

-3.7%

Last 90 days

-6.8%

Trailing 12 Months

20.7%

How does VRTX drawdown profile look like?

VRTX Financial Health

Current Ratio

3.99

VRTX Investor Care

Shares Dilution (1Y)

0.47%

Diluted EPS (TTM)

13.89

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	9.2B	9.5B	9.7B	9.9B
2022	7.9B	8.4B	8.7B	8.9B
2021	6.4B	6.7B	7.1B	7.6B
2020	4.8B	5.4B	6.0B	6.2B
2019	3.3B	3.5B	3.6B	4.2B
2018	2.4B	2.6B	2.8B	3.0B
2017	2.0B	2.1B	2.3B	2.5B
2016	1.3B	1.6B	1.7B	1.7B
2015	600.5M	628.1M	759.0M	1.0B
2014	1.0B	829.7M	787.0M	580.4M
2013	1.4B	1.3B	1.2B	1.2B
2012	1.8B	2.1B	1.8B	1.5B
2011	194.6M	277.4M	912.8M	1.4B
2010	100.3M	112.9M	111.7M	143.4M
2009	157.1M	138.7M	120.3M	101.9M
2008	0	0	0	175.5M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Vertex Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 02, 2024	ambrose kristen	sold	-100,560	419	-240	svp & chief accounting officer
Apr 01, 2024	ambrose kristen	sold (taxes)	-94,072	418	-225	svp & chief accounting officer
Feb 26, 2024	ambrose kristen	sold	-375,893	425	-883	svp & chief accounting officer
Feb 26, 2024	tatsis ourania	sold	-150,698	425	-354	evp, chief reg. & quality off.
Feb 26, 2024	sachdev amit	sold	-1,278,800	425	-3,004	evp chief patient & ext af off
Feb 26, 2024	arbuckle stuart a	sold	-2,142,970	425	-5,034	evp, coo
Feb 26, 2024	atkinson edward morrow iii	sold	-375,893	425	-883	evp, chief technical ops. off.
Feb 26, 2024	altshuler david	sold	-1,804,540	425	-4,239	evp, global research and cso
Feb 23, 2024	atkinson edward morrow iii	sold (taxes)	-714,181	431	-1,654	evp, chief technical ops. off.
Feb 23, 2024	ambrose kristen	sold (taxes)	-357,522	431	-828	svp & chief accounting officer

Which funds bought or sold VRTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	Legal Advantage Investments, Inc.	added	38.11	225,829	764,958	0.43%
Apr 23, 2024	Venturi Wealth Management, LLC	added	0.39	29,260	962,260	0.06%
Apr 23, 2024	BFSG, LLC	new	-	22,573	22,573	-%
Apr 23, 2024	LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA	added	2.19	-13,504	223,555	-%
Apr 23, 2024	FIFTH THIRD BANCORP	reduced	-1.17	168,782	11,178,000	0.04%
Apr 23, 2024	Global Retirement Partners, LLC	added	11.03	31,366	547,350	0.02%
Apr 23, 2024	Peak Financial Management, Inc.	new	-	234,086	234,086	0.07%
Apr 23, 2024	Gradient Investments LLC	reduced	-75.32	-46,777	15,884	-%
Apr 23, 2024	Covenant Asset Management, LLC	added	7.07	459,579	5,055,000	0.83%
Apr 23, 2024	Strategic Blueprint, LLC	added	46.34	134,370	401,290	0.03%

Are Funds Buying or Selling VRTX?

Are funds buying VRTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VRTX

No. of Funds

VRTX Alerts

1 major insider sales recently.

Unveiling Vertex Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 10, 2024	capital world investors	10.0%	25,902,938	SC 13G/A
Feb 13, 2024	vanguard group inc	8.65%	22,281,729	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 09, 2024	capital world investors	8.6%	22,080,207	SC 13G/A
Jan 25, 2024	blackrock inc.	8.5%	21,881,203	SC 13G
Feb 13, 2023	capital world investors	5.0%	12,939,319	SC 13G
Feb 09, 2023	fmr llc	-	0	SC 13G
Feb 09, 2023	vanguard group inc	8.39%	21,546,903	SC 13G/A
Jan 24, 2023	blackrock inc.	9.4%	24,241,437	SC 13G
Feb 14, 2022	price t rowe associates inc /md/	2.1%	5,421,291	SC 13G/A

Recent SEC filings of Vertex Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	SC TO-T	SC TO-T
Apr 17, 2024	4	Insider Trading
Apr 16, 2024	PX14A6G	PX14A6G
Apr 11, 2024	8-K	Current Report
Apr 11, 2024	SC TO-C	SC TO-C
Apr 11, 2024	SC TO-C	SC TO-C
Apr 10, 2024	SC 13G/A	Major Ownership Report
Apr 10, 2024	SC TO-C	SC TO-C
Apr 04, 2024	ARS	ARS
Apr 04, 2024	DEF 14A	DEF 14A

Peers (Alternatives to Vertex Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	-1.39%	-19.31%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.44%	-28.86%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	5.41%	-4.57%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.99%	-29.65%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-10.10%	-42.90%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-14.83%	70.74%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-7.99%	-0.08%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.49%	-30.64%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-7.01%	-17.50%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.67%	-6.03%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-13.72%	-45.61%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	-0.25%	294.45%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-18.06%	3.25%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	70.91%	57.98%	-0.24	2.14	-13.45%	66.37%

Vertex Pharmaceuticals Inc News

Latest updates

Vertex Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	1.4%	2,518	2,484	2,493	2,375	2,303	2,334	2,196	2,098	2,073	1,984	1,793	1,724	1,628	1,538	1,524	1,515	1,413	950	941	858	870
Costs and Expenses	5.8%	1,529	1,445	1,467	1,596	1,269	1,208	1,090	1,057	1,195	930	1,831	837	882	866	806	795	862	850	671	582	742
S&GA Expenses	39.9%	369	264	263	241	267	247	215	215	255	198	195	192	212	185	192	182	195	160	157	147	153
R&D Expenses	-	-	-	-	-	-	-	-	603	694	494	1,407	456	467	493	421	449	480	556	379	339	438
EBITDA Margin	-0.1%	0.46*	0.46*	0.46*	0.46*	0.48*	0.47*	0.48*	0.37*	0.37*	0.40*	0.37*	0.52*	-	-	-	-	-	-	-	-	-
Interest Expenses	2.8%	-10.60	-10.90	-11.20	-11.40	-11.60	-13.70	-14.60	-14.90	-15.10	-15.20	-15.50	-15.70	16.00	-13.86	-13.87	-14.14	14.00	15.00	15.00	15.00	19.00
Income Taxes	24.3%	179	144	246	192	258	246	214	193	101	231	-111	168	284	78.00	-12.50	55.00	94.00	13.00	60.00	52.00	-1,492
Earnings Before Taxes	-2.7%	1,148	1,179	1,162	892	1,077	1,176	1,024	955	871	1,083	-44.20	821	889	746	825	658	677	71.00	327	320	32.00
EBT Margin	-0.6%	0.44*	0.45*	0.45*	0.45*	0.47*	0.46*	0.47*	0.36*	0.36*	0.39*	0.36*	0.51*	-	-	-	-	-	-	-	-	-
Net Income	-6.4%	969	1,035	916	700	819	931	811	762	770	852	67.00	653	604	667	837	603	583	58.00	267	269	1,551
Net Income Margin	2.0%	0.37*	0.36*	0.35*	0.35*	0.37*	0.38*	0.38*	0.31*	0.31*	0.31*	0.30*	0.43*	-	-	-	-	-	-	-	-	-
Free Cashflow	-85.6%	177	1,228	1,075	858	1,045	901	1,087	893	933	875	-249	850	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	4.6%	22,730	21,726	20,349	18,974	18,151	16,706	15,582	14,256	13,433	12,619	12,222	12,115	11,752	11,302	10,216	8,893	8,318	7,515	7,033	6,543	6,262
Current Assets	-3.8%	14,144	14,696	13,873	12,966	13,235	12,271	11,504	10,361	9,561	8,853	8,458	8,539	8,133	7,458	6,694	5,446	4,823	4,777	4,711	4,183	3,843
Cash Equivalents	-6.7%	10,369	11,110	10,151	9,290	10,504	9,172	8,702	7,600	6,795	6,276	6,064	6,304	5,988	5,358	4,831	3,593	3,109	3,398	3,295	2,894	2,650
Inventory	7.3%	739	689	604	535	461	388	368	339	353	333	322	299	281	245	219	187	168	162	143	137	124
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	921	728	736	745	17.00	731	743	812
Goodwill	1.1%	1,100	1,088	1,088	1,088	1,088	86.00	1,002	1,002	1,002	1,002	1,002	1,002	1,000	1,002	1,002	1,002	1,000	448	50.00	50.00	50.00
Liabilities	-1.2%	5,150	5,213	4,879	4,542	4,238	3,677	3,649	3,349	3,333	3,088	3,025	3,135	3,065	3,168	2,697	2,432	2,233	2,261	1,964	1,820	1,811
Current Liabilities	-1.4%	3,547	3,599	3,352	3,026	2,742	2,609	2,556	2,180	2,142	1,914	1,836	1,944	1,878	2,004	1,799	1,539	1,335	1,389	1,259	1,106	1,120
Shareholder's Equity	6.5%	17,580	16,513	15,470	14,432	13,913	13,030	11,934	10,907	10,100	9,531	9,196	8,980	8,687	8,133	7,519	6,462	6,085	5,253	5,070	4,723	4,435
Retained Earnings	10.6%	10,142	9,174	8,138	7,223	6,523	5,704	4,773	3,963	3,201	2,431	1,579	1,512	859	254	-412	-1,250	-1,852	-2,436	-2,493	-2,761	-2,989
Additional Paid-In Capital	1.5%	7,450	7,340	7,369	7,220	7,387	7,226	7,100	6,930	6,881	7,086	7,640	7,499	7,894	7,917	7,944	7,696	7,938	7,668	7,564	7,476	7,421
Shares Outstanding	-0.1%	258	258	258	258	257	257	256	255	258	258	259	259	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	90,700	-	-	-	71,800	-	-	-	51,600	-	-	-	74,800	-	-	-	46,700	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-81.5%	235	1,268	1,134	900	1,078	956	1,140	956	995	927	-199	921	492	908	1,039	816	446	335	464	325	315
Share Based Compensation	59.4%	209	131	119	122	112	136	114	130	119	103	105	115	97.00	100	117	116	92.00	85.00	90.00	94.00	79.00
Cashflow From Investing	-653.2%	-886	-117	-303	-1,833	176	-384	-61.50	-51.00	-134	-52.90	-79.70	-74.30	244	-247	72.00	32.00	-896	-249	-50.19	-39.14	-40.90
Cashflow From Financing	27.4%	-119	-165	17.00	-294	40.00	-60.20	48.00	-95.40	-336	-656	34.00	-518	-125	-140	120	-359	161	20.00	-13.01	-41.99	-101
Buy Backs	20.2%	148	123	26.00	133	-	-	-	-	363	642	-	425	131	108	-	300	32.00	12.00	52.00	94.00	142

VRTX Income Statement

2023-12-31

Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Revenue	$ 9,869.2	$ 8,930.7	$ 7,574.4
Costs and expenses:
Cost of sales	1,262.2	1,080.3	904.2
Research and development expenses	3,162.9	2,540.3	1,937.8
Acquired in-process research and development expenses	527.1	115.5	1,113.3
Selling, general and administrative expenses	1,136.6	944.7	840.1
Change in fair value of contingent consideration	(51.6)	(57.5)	(3.1)
Total costs and expenses	6,037.2	4,623.3	4,792.3
Income from operations	3,832.0	4,307.4	2,782.1
Interest income	614.7	144.6	4.9
Interest expense	(44.1)	(54.8)	(61.5)
Other (expense) income, net	(22.8)	(164.8)	4.9
Income before provision for income taxes	4,379.8	4,232.4	2,730.4
Provision for income taxes	760.2	910.4	388.3
Net income	$ 3,619.6	$ 3,322.0	$ 2,342.1
Net income per common share:
Basic (in dollars per share)	$ 14.05	$ 12.97	$ 9.09
Diluted (in dollars per share)	$ 13.89	$ 12.82	$ 9.01
Shares used in per share calculations:
Basic (in shares)	257.7	256.1	257.7
Diluted (in shares)	260.5	259.1	259.9
Product revenues, net
Revenues:
Revenue	$ 9,869.2	$ 8,930.7	$ 7,573.4
Other revenues
Revenues:
Revenue	$ 0.0	$ 0.0	$ 1.0

VRTX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 10,369.1	$ 10,504.0
Marketable securities	849.2	274.5
Accounts receivable, net	1,563.4	1,442.2
Inventories	738.8	460.6
Prepaid expenses and other current assets	623.7	553.5
Total current assets	14,144.2	13,234.8
Property and equipment, net	1,159.3	1,108.4
Goodwill	1,088.0	1,088.0
Other intangible assets, net	839.9	603.6
Deferred tax assets	1,812.1	1,246.9
Operating lease assets	293.6	347.4
Long-term marketable securities	2,497.8	112.2
Other assets	895.3	409.6
Total assets	22,730.2	18,150.9
Current liabilities:
Accounts payable	364.9	303.9
Accrued expenses	2,655.3	2,126.7
Other current liabilities	527.2	311.5
Total current liabilities	3,547.4	2,742.1
Long-term finance lease liabilities	376.1	430.8
Long-term operating lease liabilities	348.6	379.5
Other long-term liabilities	877.7	685.8
Total liabilities	5,149.8	4,238.2
Commitments and contingencies	0.0	0.0
Shareholders’ equity:
Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding	0.0	0.0
Common stock, $0.01 par value; 500,000,000 shares authorized, 257,695,221 and 257,011,628 shares issued and outstanding, respectively	2.6	2.6
Additional paid-in capital	7,449.7	7,386.5
Accumulated other comprehensive (loss) income	(14.3)	0.8
Retained earnings	10,142.4	6,522.8
Total shareholders’ equity	17,580.4	13,912.7
Total liabilities and shareholders’ equity	$ 22,730.2	$ 18,150.9

About Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

CEO	Dr. Reshma Kewalramani FASN, M.D.
WEBSITE	vrtx.com
INDUSTRY	Biotechnology
EMPLOYEES	4800

Vertex Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Vertex Pharmaceuticals Inc? What does VRTX stand for in stocks?

VRTX is the stock ticker symbol of Vertex Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vertex Pharmaceuticals Inc (VRTX)?

As of Wed Apr 24 2024, market cap of Vertex Pharmaceuticals Inc is 103.52 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VRTX stock?

You can check VRTX's fair value in chart for subscribers.

What is the fair value of VRTX stock?

You can check VRTX's fair value in chart for subscribers. The fair value of Vertex Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Vertex Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VRTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Vertex Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether VRTX is over valued or under valued. Whether Vertex Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Vertex Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VRTX.

What is Vertex Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, VRTX's PE ratio (Price to Earnings) is 28.6 and Price to Sales (PS) ratio is 10.49. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VRTX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Vertex Pharmaceuticals Inc's stock?

In the past 10 years, Vertex Pharmaceuticals Inc has provided 0.201 (multiply by 100 for percentage) rate of return.